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Abstract 12 
We report the self-assembly of anti-cancer drug-loaded solid lipid nanoparticles (SLNs) from spray dried 13 
microparticles comprising poly(vinylpyrrolidone) (PVP) loaded with glyceryl tristearate (GTS) and either 14 
indomethacin (IMC) or 5-fluorouracil (5-FU). When the spray dried microparticles are added to water, the 15 
PVP matrix dissolves and the GTS and drug self-assemble into SLNs. The SLNs provide a non-toxic delivery 16 
platform for both hydrophobic (indomethacin) and hydrophilic (5-fluorouracil) drugs. They show extended 17 
release profiles over more than 24 h, and in permeation studies the drug cargo is seen to accumulate inside 18 
cancer cells. This overcomes major issues with achieving local intestinal delivery of these active ingredients, 19 
in that IMC permeates well and thus will enter the systemic circulation and potentially lead to side effects, 20 
while 5-FU remains in the lumen of the small intestine and will be secreted without having any therapeutic 21 
benefit. The SLN formulations are as effective as the pure drugs in terms of their ability to induce cell death. 22 
Our approach represents a new and simple route to the fabrication of SLNs: by assembling these from spray-23 
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1.  Introduction 30 
Solid lipid nanoparticles (SLNs) are colloidal drug carriers of size between 50 – 400 nm which have 31 
been much explored as an alternative to emulsions, liposomes, and polymeric particles. They contain 32 
solid lipids such as fatty acids, steroids, glycerides and waxes in place of the liquid lipids which are 33 
employed for other formulations (Muller et al., 1995). SLNs are advantageous over other lipid-based 34 
systems in terms of their small size, large surface area, and high biocompatibility (owing to the low 35 
toxicity of their components) (Mehnert and Mäder, 2001). In addition, they can provide highly 36 
controlled drug delivery. There is thus great interest in the use of SLNs as drug nanocarriers 37 
(Mukherjee et al., 2009), for instance in the improvement of treatments for various types of cancer 38 
(Chen et al., 2001; Kang et al., 2010; Lee et al., 2007; Yang et al., 1999). However, there are a number 39 
of drawbacks to SLNs, including a limited drug-loading capacity and sometimes rapid expulsion of the 40 
encapsulated drug. A major problem is the commonly reported gelation of SLN dispersions, and a 41 
marked increase of their particle size upon storage owing to poor colloidal stability (Das and 42 
Chaudhury, 2011). 43 
 44 
The most common processes for fabricating SLNs are high pressure homogenization or sonication 45 
(Mehnert and Mäder, 2001, 2012). Both involve melting the lipid and drug, followed by the formation 46 
of an emulsion by dispersing the melt into a hot aqueous surfactant solution. Subsequent cooling of 47 
the emulsion allows the solidification of the lipid, giving an aqueous dispersion of SLNs. These 48 
aqueous dispersions can then be converted into a dry powder to improve storage stability (Mehnert 49 
and Mäder, 2001, 2012). This multi-step process is time consuming and expensive however, and the 50 
use of heat can be problematic for thermally labile drugs. Alternative SLN manufacturing processes 51 




One alternative approach to SLN fabrication involves the use of polymer-based microcomposites as 54 
sacrificial templates. In this paradigm, a fast-dissolving hydrophilic matrix containing the drug and 55 
lipid as a molecular dispersion is first prepared, and then added to water. As the hydrophilic matrix 56 
takes up water, the hydrophobic components (the drug and lipid) cluster together and self-assemble 57 
into SLNs. This route has been proven viable using polymer composites generated by 58 
electrohydrodynamic (EHD) approaches, as reported by Yu et al. (Yu et al., 2011a). However, although 59 
EHD approaches are increasingly recognised as being scalable from the lab bench to industrial 60 
production volumes (Démuth et al., 2016; Farkas et al., 2019; Valtera et al., 2019; Vass et al., 2019), 61 
the vast majority of research on them has to date been performed at small scale, and the techniques 62 
have yet to be adopted by the pharmaceutical industry. 63 
 64 
In contrast, the spray drying approach to preparing polymer-based composites is widely used in the 65 
pharmaceutical (and food) industries for a variety of applications (Poozesh and Bilgili, 2019; Ziaee et 66 
al., 2019). It involves rapid evaporation of the solvent from a solution, and results in spherical 67 
particles of around 1 – 5 µm in size.  Spray drying has extensively explored to generate formulations 68 
of active pharmaceutical ingredients (APIs), with systems containing etravirine, ivacaftor, tacrolimus, 69 
itraconazole, and everolimus, among many others, having been reported (Newman, 2015; Ziaee et 70 
al., 2019). Typically spray dried microparticles comprise amorphous solid dispersions, offering 71 
advantages in solubility and dissolution rate over other formulation approaches.  72 
 73 
Spray drying has also been studied for developing SLN and other nanoparticulate-based formulations. 74 
There are four different approaches that can be envisaged. In the first (Figure 1(a)), a suspension of 75 
SLNs can be spray dried into a dry reconstitutable powder. This has been reported on a number of 76 
occasions, but obstacles such as particle growth have been encountered as a consequence of the use 77 
of high temperatures and the resultant melting of the lipid phase (Salminen et al., 2019).  Extensive 78 
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optimisation is also required (Xia et al., 2016). The second method uses the spray-drying technique 79 
for the top-down preparation of nanoparticle-loaded polymer microparticles, by processing 80 
suspensions of nanoparticles in a polymer solution (see Figure 1(b)). The resultant formulations have 81 
been found to have potential for the formulation of APIs for delivery by multiple administration 82 
routes (Müller et al., 2000). Both these methods require the SLNs to be prepared prior to spray 83 
drying, rendering them rather complex multi-step processes.  84 
 85 
A potentially more interesting application of spray drying is its putative use in the bottom-up self-86 
assembly of nanoscale objects. In the case of SLNs, this would involve processing a solution of drug, 87 
lipid, and polymer. These could either self-assemble into SLNs during the drying process (Figure 1(c)), 88 
or produce a molecular dispersion of drug and lipid in polymer (Figure 1(d)). Such bottom-up self-89 
assembly is a much simpler route to nanoscale systems than the top-down method, and can be 90 
completed in two steps (preparation of the microparticles, and then addition of the solvent).  There 91 
are several reports of the former in the literature. For instance, Pansare et al. have used this to self-92 
assemble nanocrystals of phenytoin in a hydroxypropyl methylcellulose / poly(lactic acid)-93 
poly(ethylene glycol) block copolymer by spray drying (Pansare et al., 2018), while Liu and co-workers 94 
have generated core/shell microparticles with a Eudragit RS shell and silica sol core (Liu et al., 2011). 95 
In both cases, complex architectures could be obtained in a single step during drying. In related work, 96 
Suhendi et al. were able to assemble silica nanoparticles and polystyrene spheres during the spray 97 
drying process (Suhendi et al., 2013), and Fatnassi combined sol-gel approaches with spray-drying to 98 
obtain drug-loaded nanostructured microparticles (Fatnassi et al., 2010). 99 
 100 
To date, to the best of our knowledge, there are no reports in the literature of the final situation, in 101 
which a molecular dispersion is generated by spray drying and then self-assembles upon addition to 102 
water. There are also no reports of self-assembling SLNs in spray drying, despite the great benefits 103 
of these systems. In this work, we sought for the first time to self-assemble SLNs from spray dried 104 
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formulations. To do this, we employed the hydrophilic polymer poly(vinylpyrrolidone) (PVP), the solid 105 
lipid glyceryl tristearate (GTS), and either 5-fluorouracil (5-FU) or indomethacin (IMC), two drugs with 106 
potential in the treatment of colon cancer (Foley et al., 2008; Hull et al., 2003; Wang and DuBois, 107 
2006). We hypothesised that the PVP-based microparticles produced could act as “proto-SLNs”, 108 
allowing us to produce formulations which are long-term stable and can be converted to SLNs on 109 
demand. 110 





Figure 1: Schematic illustrations of the different approaches to produce drug-loaded SLN-based formulations by spray drying (SD). (a) 114 
A suspension of drug-loaded SLNs can be converted into a powder; (b) a suspension of drug-loaded SLNs in a polymer solution yields 115 
SLN/polymer composites, which can later dissolve to give free SLNs; (c) a solution of lipid, drug, and polymer can be converted into 116 
SLN-loaded polymer particles in the SD step, and again the latter can be dissolved in an aqueous medium to free the SLNs, and (d) a 117 
lipid/drug/polymer solution can be processed into a molecular dispersion composite, which then self-assembles into  drug-loaded 118 
SLNs when water is added. 119 
 120 
2.  Materials and methods 121 
2.1 Synthetic procedures 122 
Solutions containing indomethacin (IMC, Alfa Aesar) or 5-fluorouracil (5-FU, Sigma-Aldrich) were prepared 123 
prior to the spray drying process. These solutions were composed of the drug, polyvinylpyrrolidone (PVP, 40 124 
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kDa, Sigma-Aldrich) and glyceryl tristearate (GTS, Sigma-Aldrich). Chloroform was used as the solvent for IMC. 125 
In the case of 5-FU, the drug was fully dissolved in dimethylformamide (DMF) and then mixed with a PVP/GTS 126 
solution in chloroform for 10 min before spray drying. All solvents were from Fisher Scientific. The solutions 127 
contained final concentrations of 10 % w/v of polymer, 5 % w/v of GTS and 2.5 % w/v drug.  128 
 129 
Spray drying was performed using a mini spray dryer (Buchi B-290, Laboratory-Technik Ltd) with a closed 130 
loop. The spray nozzle tip diameter was 0.7 mm. The inlet air temperature was 70 °C and the outlet air 131 
temperature 40–48 °C. The liquid feed rate to the dryer was 10 mL min−1, and the flow of drying gas 132 
approximately 35 m3 h-1. Experiments were performed under constant process conditions. After letting the 133 
equipment cool down to below 50 °C, the dry powder was collected from the particle chamber. The material 134 
obtained was stored in a desiccator containing silica gel until required for further use. The yield from spray 135 
drying was ca. 35 % w/w. 136 
 137 
For the self-assembly process, 10 mg of the spray dried formulations was accurately weighed, added to 10 138 
mL of distilled water, and sonicated for 10 min to assist with the formation of SLNs. The resultant suspension 139 
was then filtered using a 0.22 µm syringe filter.  140 
 141 
2.2 Scanning electron microscopy 142 
The spray dried particles were analysed by scanning electron microscopy (SEM), which was performed using 143 
a field emission microscope (FEI Quanta 200F) connected to a secondary electron detector. Samples were 144 
adhered to a SEM stub with carbon-coated double-sided tape, and sputter coated with gold to render them 145 
conductive prior to measurement. Particle diameters were measured using the ImageJ software (National 146 
Institutes of Health). At least 100 particles were measured, and the values are reported as mean ± standard 147 




Focused ion beam (FIB) SEM was performed by mounting samples on adhesive carbon coated aluminium 150 
pads and coating them with carbon in a Balzers CED 030 carbon evaporator. FIB-SEM was then undertaken 151 
in a FEI Quanta 3D FEG instrument, by first sputtering the particles of interest with platinum and subsequently 152 
ablating with Ga3+ ions. 153 
 154 
2.3 Transmission electron microscopy 155 
One drop of the self-assembled SLN suspension was mixed with a drop of 1 % w/v aqueous uranyl acetate 156 
solution, and the resultant mixture dropped on a carbon-coated copper grid. Transmission electron 157 
microscopy (TEM) was undertaken on a JEOL KEM-2100F microscope.  158 
 159 
2.4 Differential scanning calorimetry  160 
Thermograms were obtained on a Q2000 differential scanning calorimeter (DSC, TA Instruments). Around 2-161 
5 mg of sample was placed in a non-hermetically sealed aluminium pan (T130425, TA Instruments). The 162 
samples were heated from 0 – 110 °C at 10°C min-1 (to remove any adsorbed water), followed by cooling to 163 
0 °C at 10 °C min-1 and reheating to 200 °C, again at 10 °C min-1. All stages were performed under a 50 mL 164 
min-1 flow of oxygen-free nitrogen gas. The TA Universal Analysis software was used to analyse the data.  165 
 166 
2.5 X-Ray diffraction 167 
X-ray diffraction (XRD) patterns were collected on a Rigaku Miniflex 600 diffractometer supplied with Cu Kα 168 
radiation (1.5418 Å) at 40 kV and 15 mA. Patterns were recorded over the 2θ range 3 – 40° at a speed of 5° 169 
min-1.  170 
 171 
2.6  IR spectroscopy 172 





2.7 Dynamic light scattering  176 
The size of the self-assembled SLNs was quantified using dynamic light scattering (DLS) on a Zetasizer Nano 177 
ZS instrument (Malvern Instruments). Each formulation was dispersed in distilled water at a concentration 178 
of 1 mg mL-1, and a disposable polystyrene cuvette employed for sizing. The experiment was performed in 179 
triplicate, with each suspension being prepared three times. To investigate the stability of the SLNs, the 180 
suspension was stored and further DLS measurements collected after 6 months. 181 
 182 
2.8 Entrapment efficiency 183 
The entrapment efficiency (EE) was calculated as follows. 3 mL of the self-assembled SLNs were loaded into 184 
a filter centrifuge tube (Amicon Ultra-15, 3000 MWCO, Merck Millipore) and centrifuged at 9500 rpm for 10 185 
min at 25 °C, with acceleration and brake set to 9. After centrifugation, the filtrate was recovered and 186 
analysed by UV spectroscopy (Cary 100 spectrophotometer, Agilent Technologies) at 240 nm (IMC) and 265 187 
nm (5-FU). %EE was calculated using Equation 1: 188 
 189 
%𝐸𝐸 =
𝑊𝑡𝑜𝑡𝑎𝑙 𝑑𝑟𝑢𝑔 −  𝑊𝑓𝑟𝑒𝑒 𝑑𝑟𝑢𝑔 
𝑊𝑡𝑜𝑡𝑎𝑙 𝑑𝑟𝑢𝑔
 𝑥 100 190 
Equation 1 191 
Wtotal drug represents the overall mass of drug in the formulation, Wfree drug is the mass of drug present in the 192 
supernatant. 193 
 194 
2.9 Drug release studies 195 
5 mL of the aqueous SLN suspension was transferred into a cellulose dialysis bag (Fisher Scientific, 3500 196 
MWCO, volume/cm=1.5). The latter was then placed in an autoclave bottle containing 50 mL of phosphate 197 
buffered saline (PBS; pH 6.8) or fasted state simulated intestinal fluid, FaSSIF (Biorelevant) at 37 °C, and 198 
stirred at 80 rpm. 2 mL aliquots were withdrawn periodically and replaced with the same volume of fresh 199 
preheated media. The aliquots were filtered (0.22 µm filter) and the drug concentration quantified by UV-vis 200 
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spectroscopy (Cary 100 spectrophotometer, Agilent Technologies). Experiments were performed in triplicate 201 
and data are presented as mean ± S.D. 202 
 203 
2.10 Cell culture  204 
The colorectal adenocarcinoma cell line Caco-2 (ATCC HTB-37) was employed for in vitro studies. Cells were 205 
maintained at 37 °C, under 5 % CO2, in Dulbecco’s modified Eagle’s medium (DMEM-HG; Gibco) 206 
supplemented with penicillin-streptomycin (1 % v/v) and L-glutamine (1 % v/v) solutions, non-essential amino 207 
acid solution (1 % v/v) (all Life Technologies), and 10 % v/v heat-inactivated fetal bovine serum (Gibco) 208 
(termed “complete DMEM”). Cells were passaged until required for further studies. This process involved a 209 
treatment with 0.05 % trypsin-EDTA solution. The passage numbers for the viability experiments were 210 
between 26 and 30. 211 
 212 
The human dermal fibroblast (HDF) cell line was purchased from Life Technologies (lot 771555). The cells 213 
were maintained at 37 °C, under a 5 % CO2 atmosphere, in Dulbecco’s modified Eagle’s medium-high glucose 214 
(DMEM-HG) supplemented with 10 % (v/v) heat-inactivated fetal bovine serum (Gibco), 2 mM L-1 glutamine, 215 
1 % v/v MEM non-essential amino acids, gentamicin solution (100 μg mL-1) and amphotericin B solution (0.25 216 
μg mL-1) (all Life Technologies). Cells were passaged when a confluence of 70 – 80 % was reached through 217 
treatment with 0.05 % trypsin-EDTA solution. The passage number for the viability experiments was between 218 
20 and 25.  219 
 220 
For viability tests, Biolite 24 well multidish clear plates (ThermoFisher) were used. The seeding density was 5 221 
x 104 cells mL-1, and each well contained 1 mL of media. The formulations to be tested were dispersed in 222 
complete DMEM (1 mg mL-1), filtered through a 0.22 µm filter, and 180 µL of the resultant SLN suspension 223 
was added to the wells of the plate. The cells were incubated with the dissolved formulations for 48 h. Cell 224 
viability was determined using the Alamar Blue™ cell viability assay (ThermoFisher). The reagent was 225 
prepared following the manufacturer’s instructions, and added to the culture plates with a reagent volume 226 
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equal to the volume of cell culture medium present in each well. After addition, the plate was incubated for 227 
60 minutes at 37 °C and 5 % CO2 before absorbance at 570 nm and 600 nm was read using a SpectraMax M2e 228 
spectrophotometer (Molecular Devices). The viability of the cells was calculated using the Equation 2. 229 
 230 
% 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =
100 × (𝐴570,𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 − 𝐴600,𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠)
(𝐴570,𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 − 𝐴600,𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠)
 231 
Equation 2 232 
2.11 Permeation assays 233 
Caco-2 cells were grown in complete DMEM in a Falcon® 24-multiwell insert system plate (Corning) for 21 234 
days, changing the medium every 2 days. The seeding density was 3.75 x 104 cells cm-2. On the day of the 235 
assay, the Caco-2 monolayer was washed twice with transport buffer (Hanks Balanced Salt Solution 236 
supplemented with 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid and with the pH adjusted to 237 
7.4). The cells were left to equilibrate for 30 min at 37 °C. The assay was initiated when the donor solution 238 
(containing 200 µM of the drug) was placed on the apical side of the monolayer, and samples of 250 µL were 239 
withdrawn from the basal side at different time points over 2 h. Fresh buffer was supplied at each time to 240 
maintain a constant volume. The transepithelial electrical resistance (TEER) was measured before and after 241 
the experiment to assess the integrity of the monolayer. All experiments were performed in triplicate. 242 
 243 








Equation 3 246 
 247 
Where dQ/dt is the steady state flux (µmol s-1) and C0 is the initial concentration in the donor chamber (µM), 248 




Samples obtained from the permeation studies were subjected to a liquid-liquid extraction using ethyl 251 
acetate as the organic solvent. After the addition of ethyl acetate (2 mL) to each sample, they were vortexed 252 
for 2 min and then left to separate and for the organic layer to evaporate.  The latter was accelerated using 253 
a stream of air.  254 
 255 
2.12 High performance liquid chromatography 256 
High performance liquid chromatography (HPLC) was performed on the permeation study samples using 257 
previously published and validated methods (Nassim et al., 2002). The residue from liquid-liquid extraction 258 
was first reconstituted in an appropriate mobile phase. The IMC mobile phase comprised 0.5 % v/v aqueous 259 
orthophosphoric acid, methanol, and acetonitrile (all Fisher) at volume ratios of 40: 20: 40. For 5-FU the 260 
mobile phase was acetonitrile: water (10: 90 v/v). For both analyses, a Luna C18 column (Phenomenex) was 261 
utilised with an injection volume of 10 µL. IMC experiments were undertaken at a flow rate of 2 mL min-1, 262 
and 5-FU chromatograms recorded at a flow rate of 1 mL min-1 (Tsvetkova, 2012). 263 
 264 
2.13 Stability studies 265 
The stability of the SLNs was assessed by measuring their size immediately after fabrication, and after storage 266 
at room temperature for 6 months. The spray-dried microparticles were also stored under the same 267 
conditions, and a fresh batch of SLNs assembled from them after 6 months. The size of the SLNs was 268 
determined by DLS in each case. 269 
 270 
2.14 Statistical analysis 271 
Size data obtained from DLS were analysed using a one tailed Student’s t-test. The level of significance was 272 
set at p < 0.05. Data from cell culture experiments were statistically analysed using the MiniTab17 Software. 273 
The statistical significance of differences was evaluated by one-way ANOVA using Dunnett simultaneous 95% 274 




3.  Results and discussion 277 
3.1 Spray drying 278 
The production of PVP/GTS/drug particles by spray drying was found to be facile (see Figure 2). Three 279 
formulations were prepared, comprising PVP/GTS alone (SD-PVP-GTS), and PVP and GTS with IMC (SD-IMC) 280 
or 5-FU (SD-5FU). All three formulations comprise spherical particles with an average size of 6.61 ± 4.16 µm 281 
for SD-PVP-GTS, 7.15 ± 4.39 µm for SD-IMC, and 5.78 ± 4.44 µm for SD-5FU (PDIs: 0.63, 0.61 and 0.77, 282 
respectively). A wide range of particle sizes have clearly formed, and in addition a few very fine fibres (due 283 
to the high molecular weight of the polymer used) can be seen in all cases. 284 
 285 
   
Figure 2: SEM images of the spray-dried formulations. SD-PVP-GTS contains PVP and GTS alone, while SD-IMC and SD-5FU also include 286 
a drug (indomethacin or 5-fluorouracil respectively). 287 
 288 
The physical form of the components in the microparticles was explored using differential scanning 289 
calorimetry (DSC) and X-ray diffraction (XRD). DSC thermograms are given in Figure 3. PVP is clearly 290 
amorphous: no melting peaks can be seen. The IMC data display a sharp endotherm at 161.7 °C due 291 
the melting of the γ-form of IMC (Dupeyrón et al., 2013). 5-FU similarly shows a sharp melting 292 
endotherm at 284 °C, again in agreement with the literature (Kalantarian et al., 2010). This confirms 293 
both to be crystalline solids. In the case of GTS, there are two endotherms (at 49 and 60 °C) and one 294 
exotherm (51.2 °C). The first endotherm indicates the melting of α-GTS, followed by recrystallisation 295 
(exotherm) to β-GTS and then melting of the latter (second endotherm) (Singh et al., 1999a, b). GTS 296 
is thus also a crystalline material. In the case of the formulations, thermograms could not be obtained 297 
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at temperatures above 180 °C because PVP carbonizes at 200 °C. Thus, the 5-FU melt lies outside the 298 
heating range measured. The thermograms of the formulations show the same behaviour as GTS, 299 
with the presence of crystalline GTS clearly present. There is no IMC melting endotherm visible in SD-300 
IMC, and thus the drug is amorphous here. 301 
 302 
Figure 3: DSC thermograms showing the second heating cycle. 303 
 304 
XRD data are shown in Figure 4. IMC is a crystalline material, with numerous distinct Bragg reflections 305 
present between 10-30o, and the pattern matches that reported for the γ-form of IMC (Dupeyrón et 306 
al., 2013). 5-FU also exhibits a number of Bragg reflections, confirming its crystalline nature. GTS 307 
shows a Bragg reflection at 21.4o, indicating the semi crystalline nature of the material (Lutton, 1945). 308 
No sharp peaks are observed in the PVP pattern, with only slight haloes at around 12 and 21°,  309 
confirming it to be amorphous. Two broad halos can be observed in SD-PVP-GTS, SD-IMC and SD-5-310 
FU, one of them being a broad hump characteristic of PVP while the peak at 21.4° corresponds to 311 
GTS. After spray drying, no Bragg reflections corresponding to the APIs can be seen in SD-IMC and 312 
SD-5-FU. They are thus amorphously distributed in the SD particles. The spray drying process results 313 
in a rapid transition from solution to solid, and thus often results in predominately amorphous 314 
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materials for small molecules because there is no time for crystallisation to take place (Takeuchi et 315 
al., 2005). 316 
 317 
 318 
Figure 4: XRD patterns of the raw materials and formulations. 319 
 320 
IR spectra of the raw materials and formulations can be found in Figure 5. The PVP spectrum contains 321 
two weak broad bands at 3200 – 3600 cm-1 and 2800 – 3000 cm-1, indicating O-H and C-H stretching.  322 
The O-H stretching is believed to be due to the water adsorbed by the polymer. The peak at 1660 cm-323 
1 corresponds to C=O stretching. IMC displays peaks between 1580 – 1620 cm-1 from aromatic C=C 324 
stretching, C=O stretching at 1680 cm-1, and bands at 1261 cm-1 (asymmetric aromatic O-C 325 
stretching), 1086 cm-1 (symmetric aromatic O-H stretching) and between 2800 – 3000 cm-1 (C-H 326 
stretching). For 5-FU, the characteristic bands are at 1429 – 1600 cm-1 (C=N and C=C ring stretching 327 
vibrations), 1720 cm-1 (C=O stretching), 1345 cm-1 (pyridine vibrations) and 2989 cm-1 (N-H 328 
stretching). GTS show two strong peaks at 2917 and 2850cm-1 and a shoulder at 2960 cm-1 (C-H 329 
stretching). C=O stretching from the ester group manifests in a strong peak at 1740 cm-1. Considering 330 
the formulations, the major peaks from GTS at ca. 1740, 2917 and 2850 cm-1 can be observed. Other 331 
than these peaks, the spectra of the formulations are very similar to that of PVP. The characteristic 332 
carboxylate bands of IMC are shifted to lower wavenumbers and overlap with the carbonyl band of 333 
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PVP at 1660 cm-1 in SD-IMC. Similar observations are noted in the SD-5-FU spectrum. In both cases, 334 
this suggests the presence of interactions between the drug and polymer. This is strongly indicative 335 
that after spray drying, the composites obtained comprise homogeneous molecular dispersions of 336 
drug-in-polymer. 337 
 338 
Figure 5: IR spectra. 339 
 340 
3.2 SLN self-assembly 341 
When the microparticles are added to water, smaller spherical objects of around 100 nm in size are 342 
observed in TEM images (Figure 6 and Supplementary Information, Figure S1). The products of this 343 
process are denoted SLN-PVP-GTS (generated from the spray dried PVP/GTS formulation), SLN-IMC 344 
and SLN-5FU (formed from the IMC and 5-FU-loaded formulations respectively). These are SLNs, and 345 
the images very closely resemble those previously reported in the literature (Ali et al., 2017; Kumar 346 
and Randhawa, 2015; Vieira et al., 2016; Yuan et al., 2014). From the images, the SLNs appear to be 347 
monolithic in nature, with no evidence for any core/shell morphology or phase separation. DLS 348 
(Figure 7) revealed the size of the particles to be 219 ± 9 nm for SLN-IMC, 251 ± 25 nm for SLN-5FU 349 
and 876 ± 99 nm for SLN-PVP-GTS. The particle size is relatively homogeneous for all the drug-loaded 350 
samples, but the presence of aggregates is apparent with SLN-PVP-GTS. After filtration through a 0.22 351 




SLN-IMC and SLN-5FU, respectively. The PDIs after filtration are 0.10 ± 0.01 and 0.14 ± 0.01 for SLN-353 
IMC and SLN-5FU respectively. Any undissolved lumps and aggregates larger than 0.22 μm are 354 
removed after filtration, and thus the size distributions of the SLNs become narrower.  355 
 356 
The formation of the SLNs can be attributed to the separation of hydrophilic and hydrophobic 357 
components of the microparticles. When the PVP-based microparticles are added to water, they will 358 
rapidly take up water, swell and start to dissolve. As they do so, the hydrophobic GTS and the drug 359 
will tend to aggregate together, to minimise contact with the aqueous phase. This results in the 360 
formation of nanoparticles comprising GTS and the drug forming as the PVP matrix is wetted, 361 
disaggregates and dissolves (Yu et al., 2011b). 362 
 363 
   
Figure 6: TEM images of the self-assembled SLNs. SLN-PVP-GTS are generated from the spray dried PVP/GTS formulation, while SLN-364 
IMC and SLN-5FU are formed from the indomethacin and 5-fluoruracil-loaded formulations respectively. 365 







Figure 7: DLS data on the SLNs, with raw data shown for (a) SLN-PVP-GTS; (b) SLN-5FU; and, (c) SLN-IMC, together with (d) a summary 367 
of the particle sizes obtained.  Data are shown both before and after filtration with a 0.22 µm syringe filter. 368 
The theoretical drug loading in the formulations was 14.3 % w/w. Upon addition of SD-IMC and SD-369 
5FU to water, the entrapment efficiency (EE) into SLNs was determined to be 86.2 ± 4.8 % and 64.9 370 
± 16.7 % respectively. The EE is influenced by the properties of both the lipid and the API, and thus 371 
the higher EE for SLN-IMC can be explained by the more hydrophobic nature of IMC. These EE values 372 
are similar to those reported in the literature (Du et al., 2010; Hippalgaonkar et al., 2013). The drug 373 




3.3 Internal structure 376 
The internal structure of the spray dried SD-IMC material was explored with FIB-SEM (Figure 8). The 377 
images show the particles to have a hollow structure, with some small dark objects observable in the 378 
shell and some larger particles present in the core. The former are of the size of the SLNs, at ca. 100 379 
– 200 nm, but they are few in number. The SLN components GTS and IMC form 43 % of the particle 380 
mass, and given the relative volumes each spray dried particle should contain of the order of 104 381 
SLNs. The FIB-SEM data thus suggest that, although some SLNs may have self-assembled during the 382 
spray drying process, there is no evidence for the formation of significant numbers of nanoparticles 383 
during this procedure. The images in Figure 8 indicate that there is some phase separation in the 384 
spray-dried microparticles, which is consistent with the observation of semi-crystalline GTS in XRD 385 
and DSC. However, the fact that large numbers of SLNs cannot be observed inside the structure 386 
suggests that the situation depicted in Figure 1(d) is most likely to be correct. This is the first time 387 
that such a self-assembly process has been noted from spray dried microparticles. 388 
 389 
 390 
Figure 8: FIB-SEM images of SD-IMC. 391 
 392 
3.4 Drug release  393 
In this work, we sought to make formulations to treat cancers in the small intestine, ideally for oral 394 
delivery. The mean pH from the small intestine to the colon varies between 6.6 and 7.5 (Evans et al., 395 
1988). Therefore, in vitro drug release experiments were performed using phosphate buffered saline 396 
(PBS) at pH 6.8, and also fasted state simulated intestinal fluid (FASSIF). The latter is reported to 397 
provide a more accurate prediction of the in vivo release profile of the drug than simple PBS (Vertzoni 398 
20 
 
et al., 2005). The release plots are given in Figure 9. When using PBS, it can be observed that there 399 
was a burst release of the entrapped IMC and 5-FU from the formulations in the first 7 h, and after 400 
this period slow release over 48 h. More rapid release was seen for the pure drugs. The behaviour of 401 
SLN-IMC is very similar to this in FASSIF, while SLN-5FU is much slower to release its drug cargo than 402 
in PBS. After 48 h in FASSIF, approx. 70 % of the incorporated indomethacin and 55 % of the 5-FU is 403 




Figure 9: Drug release from the self-assembled SLNs in pH 6.8 PBS and FASSIF, showing the (a) full time-course of the experiment and 406 
(b) first 10 h (mean ± S.D. from three independent experiments).  407 
 408 
The transit times of the small intestine and colon are around 2.5-3 h and 30-40 h respectively 409 
(Camilleri et al., 1989; Degen and Phillips, 1996; Metcalf et al., 1987), meaning that maximum drug 410 
release would be reached while the formulations are still located in the intestinal tract after oral 411 
administration. The uptake and retention of the SLNs in tumour tissue should be augmented by the 412 
enhanced permeation and retention (EPR) effect, giving them ample time to free their drug cargo 413 
(Yassin et al., 2010). Other approaches to increase the delivery of the SLNs to cancer tissues such as 414 
targeting ligands or pH sensitive systems could also be applied (Kim et al., 2015; Tran et al., 2015). In 415 




3.5 In vitro cell assays 418 
3.5.1 Permeation 419 
Permeation of the SLNs was explored using Caco-2 cells. The minimum inhibitory concentrations 420 
(IC50) were first determined and found to be 7.8 mM for IMC and 1.7 mM for 5-FU. Permeation 421 
experiments were performed below these IC50 values, at 0.2 mM. The SLNs containing IMC did not 422 
appear to permeate through the cell layer: no drug was found in the receiver compartment, and only 423 
around 5 % of the initial dose was found in the donor compartment after 2 h. At the end of the 424 
permeation study, the buffer in the donor compartment was discarded and the cell monolayer was 425 
lysed. Analysis of the lysate showed that approximately 78 % of the IMC from SLN-IMC was present 426 
in the cell monolayer. Similarly, around 62 % of the 5-FU from SLN-5FU was found in the cell 427 
monolayer and approximately 12 % in the acceptor compartment. In contrast, the percentage of pure 428 
IMC in the acceptor compartment was 54 %, while for 5-FU the donor compartment contained 71 % 429 
of the drug content. Less than 8 % of IMC or 5-FU was found in the cell monolayer when they were 430 
administered in their pure forms.  431 
 432 
Assessment of the permeation of pure IMC resulted in a Papp value of 11.6 x 106 cm s-1, typical for 433 
biopharmaceutical classification system class II (BCS II) drugs and confirming the high permeability of 434 
IMC (Lee et al., 2017). In contrast, the 5-FU Papp value was 0.10 x106 cm s-1, consistent with the 435 
literature (which shows 5-FU to have poor permeability in the Caco-2 monolayer model) (Buur et al., 436 
1996). The SLNs prepared in this work thus accumulate in the cells, while IMC permeates and 5-FU 437 
remains in the donor compartment. The SLNs hence have significant advantages over either drug 438 
alone. If the IMC were to permeate through tumour cells and reach the systemic circulation, 439 
unwanted side effects could arise; the SLNs offer an alternative to preclude this. 5-FU alone does not 440 
effectively permeate, meaning that it may pass through the body without exerting a pharmacological 441 
effect. The SLNs enable both IMC and 5-FU to be effectively localised in cancer cells, ideal for the 442 




Average transepithelial resistance (TEER) values were measured at the end of the permeation 445 
experiment to verify the integrity of the monolayer. The average values for the control (untreated) 446 
Caco-2 cell monolayer before and after the permeation experiment were 395.1 ± 46.6 Ω cm2 and 447 
382.0 ± 38.2 Ω cm2, respectively. The values for SLN-IMC after the experiment were 360.9 ± 18.5 Ω 448 
cm2 and for SLN-5FU 368.1 ± 6.8 Ω cm2. It is clear that the SLNs did not have any effect on the integrity 449 




3.5.2 Viability 454 
To evaluate the ability of the formulations to kill cancerous cells, Caco-2 cells were exposed to the 455 
SLNs for 48 h, using the IC50 of each drug. The viability values obtained were compared to the pure 456 
drugs (Figure 10(a)). SLN-IMC and SLN-5FU do not show any significant differences compared to the 457 
drug alone, with cell viabilities of 58.2 ± 7.3% and 53.9 ± 7.2%, respectively. This indicates that the 458 
SLNs are as effective in causing the death of cancerous cells as the pure drug. Similar results were 459 
seen with human dermal fibroblasts (Figure 10(b)). This indicates that the SLNs are not selective in 460 
their activity, as would be expected since they are not functionalised with targeting ligands. However, 461 







Figure 10: (a) Caco-2 and (b) HDF cell viability in the presence of pure 5-FU and IMC and the drug-loaded SLNs, determined using the 465 
Alamar Blue assay. Values represent mean ± S.D. from three independent experiments with three replicates per experiment. 466 
Experiments were performed using the Caco-2 IC50 concentration of each drug. SLNs comprising only PVP and GTS gave results 467 
significantly different to those obtained with all other formulations (* denotes p < 0.05).  468 
 469 
 470 
3.6 SLN stability 471 
One of the major issues in the use of SLNs is their long-term storage stability. The stability of SLN-472 
IMC and SLN-5FU was thus assessed in terms of their hydrodynamic diameters after 6 months of 473 
storage at room temperature.  As shown in Figure 11, while the aged suspensions of SLNs show 474 
significant changes in particle size, SLNs assembled from spray dried particles aged for 6 months have 475 
virtually the same size as those assembled immediately after spray drying. In contrast, the literature 476 
reports instability of SLN suspensions of linalool over 40 days of storage (Pereira et al., 2018) and 477 
amphotericin B after 60 days storage (Santiago et al., 2018). The poor stability of SLN suspensions 478 
arises from gelation and recrystallization of the lipid phase (Siekmann and Westesen, 1994), and by 479 




Figure 11: The results of stability studies performed for 6 months at room temperature. Data are shown from 3 independent 482 
experiments as mean ± S.D. * denotes p < 0.05 with respect to those obtained at the start of the experiment (t0). 483 
 484 
4.  Conclusions 485 
Spray dried poly(vinylpyrrolidone) microparticles loaded with a drug and glyceryl tristearate have 486 
been shown to act as templates for the self-assembly of drug-loaded solid lipid nanoparticles (SLNs). 487 
The SLNs form upon addition of the spray dried particles to water, rather than during the spray-drying 488 
process itself. The SLNs provide a non-toxic delivery platform for both hydrophobic (indomethacin) 489 
and hydrophilic (5-fluorouracil) drugs. They have sustained release properties, and their drug cargo 490 
is seen to accumulate inside cancer cells. The SLN formulations are as efficacious as the pure drug in 491 
terms of their cytotoxicity. This work represents a novel alternative approach to the fabrication of 492 
SLNs. Because the SLNs are assembled from spray-dried microparticles on demand, the problems of 493 
instability upon storage which commonly arise with SLN formulations are obviated.  494 
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